Biomedical engineering graduate and certificate programs are coming to Auburn University. Led by the Department of Chemical ...
Newspoint on MSN
New BTech courses at IITs: Forget CS and mechanical—IITs have launched 10 impressive new-age courses.
New B.Tech Courses at IITs: After clearing the JEE Advanced exam, most students typically seek admission into Computer ...
VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the initiation of cell line development for its lead BiTAC ® T-cell engager ...
Anthropic AI for Science event livestreams today as the company pitches Claude to pharma and biotech leaders. The session ...
Recent advances in single-cell sequencing and spatial multi-omics have transformed our ability to resolve tumor ecosystems at unprecedented resolution.
It took a broke medical student, a $20 fish tank, and a radical idea that could one day turn failed organs into brand-new ...
Live biotherapeutics represent an emerging frontier in microbiotechnology, offering novel approaches to treat and prevent ...
"MRM Health is entering a pivotal phase, with MH002 advancing into Phase 2b clinical development and significant momentum across the business. The appointments of Michel and Hans-Jürgen significantly ...
A new method for recognizing and targeting DNA that dramatically expands the range of genetic sequences scientists can identify has been developed by experts at the University of Portsmouth. Published ...
Intellia Therapeutics is a clinical-stage leader focused on CRISPR-based gene editing to treat diseases at their genetic source. The company primarily advances therapies for hereditary angioedema (HAE ...
The Office of United States Senator Thom Tillis, the Office of United States Senator Ted Budd, the North Carolina Military Business Center, and the North Carolina Biotechnology Center will host the ...
Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC. Many biotech companies are now pursuing a dual-track ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results